Results announcement

Results for announcement to the market		
Name of issuer	AFT Pharmaceuticals Limited	
Reporting Period	6 months to 30 September 2026	
Previous Reporting Period	6 months to 30 September 2025	
Currency	New Zealand Dollars	
	Amount (000s)	**Percentage change**
Revenue from continuing operations	$143,635	24.96%
Total Revenue	$143,635	24.96%
Net profit/(loss) from continuing operations	$6,854	151.54%
Total net profit/(loss)	$6,854	151.54%
Interim/Final Dividend		
Amount per Quoted Equity Security	$0.01000000	
Imputed amount per Quoted Equity Security	$0.00388889	
Record Date	03 December 2026	
Dividend Payment Date	17 December 2026	
	Current period	**Prior comparable period**
Net tangible assets per Quoted Equity Security (in dollars and cents per security)	0.39309494	0.35867104
A brief explanation of any of the figures above necessary to enable the figures to be understood	For an explanation on AFT Pharmaceuticals operational results please refer to the accompanying NZX announcement, investor presentation and the unaudited Interim Report for the six months ended 30 September 2026.	
Authority for this announcement		
Name of person authorised to make this announcement	Stuart Houliston	
Contact person for this announcement	Stuart Houliston	
Contact phone number	+64 9 488 0232	
Contact email address	stuart.houliston@aftpharm.com	
Date of release through MAP	26 November 2026	